Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 4Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Sarcoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinoma 1Subcutaneous panniculitis-like T-cell lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Doxorubicin 141Ifosfamide 85Radiotherapy 80Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 39Etoposide 39Docetaxel 39Vincristine 37Cisplatin 35Trabectedin 32Nivolumab 32Irinotecan 26Magnetic Resonance Spectroscopy 25Carboplatin 25Temozolomide 23Ipilimumab 22Bevacizumab 20Radiation 19Granulocyte Colony-Stimulating Factor 18Surgical Procedures, Operative 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17Biopsy 17eribulin 16Specimen Handling 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Sarcoma × pirarubicin × Clear all
NCT03342300 2020-05-19

PDVPSTS

Peking University People's Hospital

Phase 2/3 Withdrawn
Sarcoma

Sarcoma

NCT04126811 2019-10-15

Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
120 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡